bpc-157 regulatory status fda 2025 panel votes to place popular peptide on compounding list FDA to weigh easing limits

8-6 vote for BPC-157 at FDA's meeting today on peptides #peptides #bpc157 #fda Yesssss

Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation

Intramuscular and subcutaneous are not interchangeable, and the needle follows the route

Obtain a serum B12 level and peripheral blood count one month after treatment initiation, then subsequently at intervals of 3 to 6 months [see Warnings and Precautions (5.3)]